CARFILZOMIB

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C40H57N5O7
Molecular Weight	719.9099
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4

InChI

InChIKey=BLMPQMFVWMYDKT-NZTKNTHTSA-N

InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C40H57N5O7
Molecular Weight	719.9099
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202714s013lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=23386784; http://www.ncbi.nlm.nih.gov/pubmed/?term=17591945

Carfilzomib is an epoxomicin derivate with potential antineoplastic activity. Kyprolis (carfilzomib's trade name) is a proteasome inhibitor that is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy as a single agent or in combination with dexamethasone or with lenalidomide plus dexamethasone. Carfilzomib is made up of four modified peptides. It irreversibly and selectively binds to N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. This 20S core has 3 catalytic active sites: the chymotrypsin, trypsin, and caspase-like sites. Inhibition of the chymotrypsin-like site by carfilzomib (β5 and β5i subunits) is the most effective target in decreasing cellular proliferation, ultimately resulting in cell cycle arrest and apoptosis of cancerous cells. At higher doses, carfilzomib will inhibit the trypsin-and capase-like sites. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
26S proteosome 7 Target ID: CHEMBL2364701 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202714s013lbl.pdf	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Multiple myeloma 159 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202714s013lbl.pdf	Secondary		Approved 8583	KYPROLIS Approved Use Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy; as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy Launch Date 2012

C_max

Value	Dose	Co-administered	Analyte	Population
519 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34470049/	70 mg/m² single, intravenous dose: 70 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		CARFILZOMIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
852 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34470049/	70 mg/m² 1 times / week multiple, intravenous dose: 70 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:		CARFILZOMIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1389 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28424963	56 mg/m² single, intravenous dose: 56 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: DEXAMETHASONE	DEXAMETHASONE	CARFILZOMIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
241 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34470049/	70 mg/m² single, intravenous dose: 70 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		CARFILZOMIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
381 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34470049/	70 mg/m² 1 times / week multiple, intravenous dose: 70 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:		CARFILZOMIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
563 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28424963	56 mg/m² single, intravenous dose: 56 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: DEXAMETHASONE	DEXAMETHASONE	CARFILZOMIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.58 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34470049/	70 mg/m² single, intravenous dose: 70 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		CARFILZOMIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.98 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34470049/	70 mg/m² 1 times / week multiple, intravenous dose: 70 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:		CARFILZOMIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.34 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28424963	56 mg/m² single, intravenous dose: 56 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: DEXAMETHASONE	DEXAMETHASONE	CARFILZOMIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
3% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf			CARFILZOMIB plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
56 mg/m2 2 times / week multiple, intravenous MTD Dose: 56 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 56 mg/m2, 2 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/27460677	unhealthy, 58 years (range:46–75 years) Health Status: unhealthy Age Group: 58 years (range:46–75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/27460677	Disc. AE: Sepsis, Colon cancer... Other AEs: Lymphopenia, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Sepsis (serious, 1 patient) Colon cancer (serious, 1 patient) Other AEs: Lymphopenia (grade 3-5, 75%) Thrombocytopenia (grade 3-5, 50%) Anaemia (grade 3-5, 50%) Neutropenia (grade 3-5, 50%) Pyrexia (grade 1-2, 75%) Blood creatinine increased (grade 1-2, 50%) White blood cell count increased (grade 1-2, 25%) White blood cell count decreased (grade 3-5, 25%) Nausea (grade 1-2, 50%) Stomatitis (grade 1-2, 50%) Neutrophil count increased (grade 1-2, 25%) Nasopharyngitis (grade 1-2, 25%) Vomiting (grade 1-2, 50%) C-reactive protein increased (grade 1-2, 50%) Hypophosphataemia (grade 1-2, 50%) Hypertension (grade 1-2, 50%) Malaise (grade 1-2, 25%) Aspartate aminotransferase increased (grade 1-2, 25%) Blood lactate dehydrogenase increased (grade 1-2, 25%) Haematocrit decreased (grade 1-2, 25%) Red blood cell count decreased (grade 1-2, 25%) Weight gain (grade 1-2, 25%) Sources: https://pubmed.ncbi.nlm.nih.gov/27460677
20 mg/m2 2 times / week steady, intravenous Recommended Dose: 20 mg/m2, 2 times / week Route: intravenous Route: steady Dose: 20 mg/m2, 2 times / week Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf	unhealthy, 63.0 years (range: 37- 87 years) Health Status: unhealthy Age Group: 63.0 years (range: 37- 87 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf	Disc. AE: Congestive heart failure, Cardiac arrest... AEs leading to discontinuation/dose reduction: Congestive heart failure (2%) Cardiac arrest (1%) Dyspnea (1%) Blood creatinine increased (1%) Acute renal failure (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf
20 mg/m2 2 times / week steady, intravenous Recommended Dose: 20 mg/m2, 2 times / week Route: intravenous Route: steady Dose: 20 mg/m2, 2 times / week Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000MedR.pdf	unhealthy, 63.0 years (range: 37- 87 years) Health Status: unhealthy Age Group: 63.0 years (range: 37- 87 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000MedR.pdf	Disc. AE: Pneumonia, Pyrexia... AEs leading to discontinuation/dose reduction: Pneumonia (2%) Pyrexia (1%) Thrombocytopenia (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000MedR.pdf
70 mg/m2 2 times / week multiple, intravenous Highest studied dose Dose: 70 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 70 mg/m2, 2 times / week Sources: https://doi.org/10.1182/blood.V118.21.2930.2930	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://doi.org/10.1182/blood.V118.21.2930.2930	DLT: Adverse event... Dose limiting toxicities: Adverse event Sources: https://doi.org/10.1182/blood.V118.21.2930.2930

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087 substrate 1946	substrate 1193 inhibitor 2438	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A4/5 296 P-gp 1741 CYP1A2 2153 CYP2C19 2057 CYP3A 227 CYP2C8 1057	peptidase 3 epoxide hydrolase 1 P-gp 2052 CYP1A2 1197 CYP2C8 810 CYP2C19 1119	CYP1A2 832

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf Page: 18.0	minor	yes (co-administration study) Comment: carfilzomib inhibits digoxin by 25% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf Page: 18.0
CYP3A4/5 357	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf Page: 18.0	moderate [IC50 0.5 uM]	no (co-administration study) Comment: carfilzomib did not affect the cmax and auc of midazolam Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf Page: 18.0
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf Page: 18.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000PharmR.pdf Page: 88.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000PharmR.pdf Page: 88.0	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000PharmR.pdf Page: 92.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000PharmR.pdf Page: 88.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000PharmR.pdf Page: 88.0	no
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf Page: 18.0	no
CYP3A 317	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000PharmR.pdf Page: 88.0	weak [IC50 3 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
epoxide hydrolase 1	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf Page: 13.0	major
peptidase 3	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf Page: 13.0	major
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000PharmR.pdf Page: 80.0	no
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000PharmR.pdf Page: 80.0	no
CYP2C8 810	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000PharmR.pdf Page: 80.0	no
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000PharmR.pdf Page: 80.0	no
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000PharmR.pdf Page: 80.0	no
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf Page: 18.0	no	no (co-administration study) Comment: carfilzomib has no effect on midazolam Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf Page: 18.0
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf Page: 18.0	yes	yes (co-administration study) Comment: ketoconazole decreased carfilzomib efflux ratio Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf Page: 18.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000SumR.pdf Page: 4.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:65347	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:65347
ChemicalBook	CB12520831	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB12520831
MolPort	MolPort-027-950-907	https://www.molport.com/shop/molecule-link/MolPort-027-950-907
Selleck Chemicals	carfilzomib-pr-171	http://www.selleckchem.com/products/carfilzomib-pr-171.html
ZINC	ZINC000049841054	http://zinc15.docking.org/substances/ZINC000049841054

PubMed

Title	Date	PubMed
Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma.	2014-05-25	24632418
Carfilzomib.	2013-02-07	23393020
A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation.	2011-06-19	21685914
New twists on proteasome inhibitors.	2010-12	21139600
Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.	2010-12	21132350
Proteasome inhibition and its therapeutic potential in multiple myeloma.	2010-09-28	21116326
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.	2010-09-15	20632995
Novel disease targets and management approaches for diffuse large B-cell lymphoma.	2010-08	20658952
Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.	2010-07	20497001
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.	2010-06-15	20694078
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.	2010-06-03	20233973
Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70.	2010-01	20066033
Relapsed multiple myeloma.	2010	21239810
State-of-the-Art Management of Complications of Myeloma and Its Treatment.	2010	20671999
Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.	2010	20166955
Bortezomib.	2010	20072838
Discovery of novel proteasome inhibitors using a high-content cell-based screening system.	2009-12-30	20041034
Future novel single agent and combination therapies.	2009-12-17	20010171
Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference.	2009-12	19943215
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.	2009-11-15	19903785
Gateways to clinical trials.	2009-11	20094643
Proteasome inhibitors in the treatment of multiple myeloma.	2009-11	19741722
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.	2009-11	19516276
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.	2009-10-15	19671918
Clinical development of novel proteasome inhibitors for cancer treatment.	2009-07	19505187
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).	2009-05-14	19348473
Gateways to clinical trials.	2009-04	19536362
New drugs in multiple myeloma and the significance of autologous stem cell transplants.	2009-03	19398940
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.	2009-03	19275578
The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.	2009	20230760
Novel therapies for relapsed myeloma.	2009	20008242
Targeting the UPS as therapy in multiple myeloma.	2008-10-21	19007431
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.	2008-10-01	18591385
Practical considerations for multiple myeloma: an overview of recent data and current options.	2008-08	18952545
Mechanisms of proteasome inhibitor action and resistance in cancer.	2008-06-24	18818117
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.	2008-06-01	18292288
The potential of proteasome inhibitors in cancer therapy.	2008-06	18491989
Gateways to clinical trials.	2008-03	18560631
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.	2007-11-01	17591945
Epoxomicin, a new antitumor agent of microbial origin.	1992-11	1468981

Patents

Sample Use Guides

In Vivo Use Guide

For monotherapy, administer Kyprolis intravenously as a 10-minute or 30-minute infusion depending on the regimen as described: for monotherapy using the 20/27 mg/m^2 regimen, administer Kyprolis intravenously as a 10-minute infusion. In Cycles 1 through 12, administer Kyprolis on two consecutive days, each week for three weeks followed by a 12-day rest period. Each 28-day period is considered one treatment cycle. From Cycle 13, omit the Day 8 and 9 doses of Kyprolis. The recommended starting dose of Kyprolis is 20 mg/m^2 in Cycle 1 on Days 1 and 2. If tolerated, escalate the dose to 27 mg/m^2 on Day 8 of Cycle 1. Treatment may continue until disease progression or unacceptable toxicity occurs. For the combination regimen with lenalidomide and dexamethasone, administer Kyprolis intravenously as a 10-minute infusion on two consecutive days, each week for three weeks followed by a 12-day rest period. Each 28-day period is considered one treatment cycle. The recommended starting dose of Kyprolis is 20 mg/m^2 in Cycle 1 on Days 1 and 2. If tolerated, escalate the dose to 27 mg/m^2 on Day 8 of Cycle 1. From Cycle 13, omit the Day 8 and 9 doses of Kyprolis. Discontinue Kyprolis after Cycle 18. Lenalidomide 25 mg is taken orally on Days 1–21 and dexamethasone 40 mg by mouth or intravenously on days 1, 8, 15, and 22 of the 28-day cycles. Continue treatment until disease progression or unacceptable toxicity occurs.

Route of Administration: Intravenous

In Vitro Use Guide

To determine whether JNK activation is important in mediating carfilzomib-induced apoptosis, RPMI 8226 cells were exposed to a pulse of 100 nM carfilzomib

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:13:00 GMT 2025` Edited by `admin` on `Mon Mar 31 18:13:00 GMT 2025`
Record UNII	72X6E3J5AR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CARFILZOMIB

Official Name

English

KYPROLIS

Preferred Name

English

CARFILZOMIB [ORANGE BOOK]

Common Name

English

PR-171

Code

English

NSC-758252

Code

English

L-PHENYLALANINAMIDE, (.ALPHA.S)-.ALPHA.-((4-MORPHOLINYLACETYL)AMINO)BENZENEBUTANOYL-L-LEUCYL-N-((1S)-3-METHYL-1-(((2R)-2-METHYLOXIRANYL)CARBONYL)BUTYL)-

Common Name

English

Carfilzomib [WHO-DD]

Common Name

English

(2S)-N-[(1S)-1-Benzyl-2-[[(1S)-3-methyl-1-[[(2R)-2-methyloxiran-2-yl]carbonyl]butyl]amino]-2-oxoethyl]-4-methyl-2-[[(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide

Common Name

English

CARFILZOMIB [MI]

Common Name

English

CARFILZOMIB [USAN]

Common Name

English

CARFILZOMIB [VANDF]

Common Name

English

CARFILZOMIB [JAN]

Common Name

English

carfilzomib [INN]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

795120